AdvaMed response letter to OMB’s RFI on deregulation, highlighting support for regulatory reform that fosters medical innovation and improved patient care, dated May 12, 2025.
Emerging Policy Response Resources / Government & Legislative Affairs / Legal

AdvaMed Comments to OMB Deregulation RFI

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.